BioSpace News Archive

Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today reported record second quarter revenues and adjusted operating income1 (“AOI”) for the three months ended September 30, 2019.

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, announced that Jill Quigley, chief operating officer, will present at the Barclays Gene Editing & Gene Therapy Summit on Wednesday, November 13th, 2019 at 9:30 a.m. ET in New York, NY..

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will webcast its presentation at two upcoming investor conferences.

Equillium, Inc. (Nasdaq: EQ), today announced that data describing the roles of the CD6-ALCAM pathway in systemic lupus erythematosus (SLE) and lupus nephritis will be presented in an oral presentation and two posters at the 2019 American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) Annual Meeting being held November 8-13, 2019 in Atlanta, GA.

NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the third quarter ended September 30, 2019 and provided an update on corporate activities.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today issued the following statement clarifying November 17, 2019 as the true deadline for Velan Capital L.P.’s (“Velan”) consent solicitation.

MannKind Corporation (NASDAQ:MNKD) today reported preliminary financial results for the quarter and nine months ended September 30, 2019.

Primmune Therapeutics announced that it will present primate pharmacology data on PRX034 at the Society for Immunotherapy of Cancer Annual Meeting 2019 in National Harbor, MD. PRX034 is a novel orally bioavailable small molecule toll-like receptor 7 agonist that activates innate immunity by systemically targeting plasmic cytoid dendritic cells in vivo.

Ryvu Therapeutics reported third quarter 2019 financial results and provided a corporate update.

Ten row crop growers each directed a $5,000 donation to a nonprofit organization of their choice as part of the Bayer Farm for Good™ Sweepstakes.